Research and drug development company Albert Labs has announced it will begin trading on the CSE.
On International Women’s Day, Psychedelic Health takes a look at just some of the women who are spearheading the psychedelic renaissance in the UK.
The philanthropic arm of atai Life Sciences, atai Impact, has donated $500,000 to The Multidisciplinary Association for Psychedelics (MAPS) for multi-year support of MAPS’ ongoing initiatives,...
The thematic ETF will track the performance of the Enhanced Consciousness Index – comprised of companies involved in the legal research, development and production of psychedelics...
Leafy Tunnel’s USD$30m (~£22.38m) fund focuses on global psychedelics opportunities alongside European medical cannabis opportunities.
Psychedelics manufacturer Psygen has received the dealer’s license for LSD, MDMA, psilocybin, psilocin, DMT, 2C-B and mescaline.
Numinus Wellness received final approval from the Toronto Stock Exchange to graduate its listing to the TSX from the TSX-Venture Exchange.
One company is providing investors with the opportunity to contribute to novel mental health care solutions by participating in the growth of companies in the psychedelics...
The acquisition includes all future worldwide rights relating to the use of psychedelics to treat Alzheimer’s disease and other dementias.
UK-based psychedelics company Albert Labs has received conditional approval for the listing of its common shares on the Canadian Securities Exchange (CSE).